Hyalo Technologies

Hyalo Technologies is a biotechnology company specializing in the development of advanced drug delivery systems using its proprietary Hyalo-Nanoparticle (HNP) platform. The company focuses on encapsulating therapeutic agents within hyaluronic acid-based nanoparticles to enhance solubility, stability, and targeted delivery to specific tissues. Their lead programs include HT-101, a topical formulation for basal cell carcinoma, and HT-201, a long-acting treatment for post-operative pain management. By leveraging the natural CD44-binding properties of hyaluronic acid, Hyalo aims to improve the efficacy of existing drugs while reducing systemic toxicity. The company is headquartered in New Jersey and operates as a private entity focused on transitioning its pipeline into clinical trials.